Ovid Therapeutics (OVID) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- —
- Estimate
- -$0.10
- Surprise
- —
- Revenue (period 2026-06-30)
- $733,000
- Score today
- 5.8/10
Revenue source: xbrl.
Coverage in the report window
- Ovid Therapeutics Q2 EPS $(0.08) Beats $(0.12) Estimate, Sales $733.000K Beat $30.000K Estimate — benzinga, 2026-08-13
Where TrendMatrix's rating stands now
TrendMatrix currently rates OVID Sell at 5.8/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate. Next scheduled report: 2027-03-17.
What argues against it
- Quality below floor (3.4 < 4.0)
- Value-trap signals (2/5): High leverage (D/E 2.8), Material insider selling (72 sells, 1.02% of cap)
- Momentum score 3.0/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $2.40
- Price target
- $5.35
- Stop
- $2.23
- Upside to target
- +122.9%
- Reward-to-risk
- 8.2:1
Model outputs from TrendMatrix’s engine as of 2026-11-17 — shown for context, not personalized investment advice.
OVID at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $479.4M
- P/E (fwd)
- -6.3
- 52-week range
- $1.21–$3.10
- Off 52-week high
- 22.7%
- RSI (14)
- 54
- Volume vs avg
- 1.04×
- Score today
- 5.8/10